SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3974How big is this market and the effects on valuation for Ariad? See post 3700, hayosarian_2-11/4/2015
3973>>And given what we know to date, I think '788 is likely a next-gen, pBiomaven-11/4/2015
3972>>The short term risk here is that their $130-$140 million revenue number Biomaven-11/4/2015
3971They re-affirmed their guidance for the year. Quite honestly modest changes in ptktom-11/4/2015
3970jaybe, I know you have been a champion of EGFR being the target for '788, butktom-11/4/2015
3969I agree, disappointing call on a few fronts. IMO postponing early ALTA readout jaybe111/3/2015
3968>>I'm quite surprised this isn't much lower in share price They rBiomaven-11/3/2015
3967Yes, the delay in partnering briga and the delay in announcing a new CEO both inBiomaven-11/3/2015
3966I'm quite surprised this isn't much lower in share price. Metrics were atktom-11/3/2015
3965On today's conference call anyone else feel that the declared lack of findinmulanoon2007-11/3/2015
3964That is interesting - of course we don't know how these patients would do onBiomaven-10/30/2015
3963An interesting report in Blood from Yeung et al this week (PMID: 26500342) follomulanoon2007-10/29/2015
3962What's for Dinner?tktom-10/24/2015
3961Dinner could have filled HB position in a NY Minute,which tells me there will becivic08801-10/24/2015
3960All the more reason that NVS want to both grow and PROTECT their Oncology pipelicivic08801-10/20/2015
3959The company doesn't have the money or the expertise to develop pona in any nBiomaven-10/19/2015
3958PON's inhibition of FGFR signaling might make it a less desirable ABL1 inhibmulanoon2007-10/18/2015
3957Oh well. With or without Ariad, this is really exciting news. npr.orgrkrw-10/18/2015
3956Biomaven, Jess, and Zuize, while there have been some researchers that for a yeatktom-10/18/2015
3955I think this could be huge for pona. I've been tracking this trial for a yejaybe110/17/2015
3954Thanks Peter! I was curious on just how much lowera dose they were using in theghmm-10/17/2015
3953If I recall correctly, Ariad has a patent for use of pona in Parkinson's. BuBiomaven110/17/2015
3952Possible other use for ponatinib? Don't know if someone has posted this somghmm-10/17/2015
3951Overstated, should have said I tried several others and found similar features, jaybe-10/17/2015
3950Thanks -- succinct & cogent! I agree with all of these things, but since 20glass 0.5 full-10/16/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News